Clik here to view.
Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to...
CAMBRIDGE, Mass. & SHANGHAI Foundation Medicine, Inc. (NASDAQ:FMI) and WuXi PharmaTech (Cayman) Inc. (NYSE:WX) today announced a collaboration to offer Foundation Medicine’s comprehensive...
View ArticleClik here to view.
Enigma Diagnostics Signs Joint Venture Agreement with Beijing Leadman...
SALISBURY, England & BEIJING Enigma Diagnostics Ltd (Enigma), a global leader in molecular diagnostic point-of-care (PoC) infectious disease testing, and Beijing Leadman Biochemistry Co., Ltd....
View ArticleClik here to view.
R-Tech Ueno: Sucampo and Takeda Enter into Global Licensing Agreement for...
TOKYO R-Tech Ueno (JASDAQ:4573): Sucampo Pharmaceuticals, Inc. (“Sucampo”) and Takeda Pharmaceutical Company Limited (Takeda) announced that on October 17, 2014, they have entered into a global...
View ArticleClik here to view.
Enigma Diagnostics与北京利德曼生化股份有限公司签署合资协议，并宣布一项5000万美元的投资
英格兰索尔兹伯里和北京 (美国商业资讯) — 分子诊断床边(point-of-care)感染性疾病检测的全球领先者Enigma Diagnostics Ltd (Enigma)与北京利德曼生化股份有限公司（Beijing Leadman Biochemistry Co.,...
View ArticleClik here to view.
CardioKinetix Initiates Study in China of First-of-Its-Kind Parachute Device...
MENLO PARK, Calif. CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced the enrollment of the first patients in PARACHUTE China, a...
View ArticleClik here to view.
CardioKinetix在中国启动治疗心力衰竭的同类器械中首款Parachute器械的研究
加州门洛帕克 (美国商业资讯) — CardioKinetix Inc.是一家心力衰竭导管治疗领域的先驱性医疗器械公司。该公司今天宣布，Parachute研究在中国入组首例患者，该研究为多中心试验，旨在评估微创Parachute®心室隔离器械用于治疗心力衰竭。 最初10例患者在北京大学和阜外医院，以及上海第十人民医院经Parachute器械进行了治疗。...
View ArticleClik here to view.
Mitsui Chemicals Launched New Lens Material “UV+420cutTM”
TOKYO Mitsui Chemicals, Inc. (TOKYO:4183) (President & CEO: Tsutomu Tannowa) announced that it commenced sales of a new breakthrough ophthalmic lens material that helps protect eyes from not...
View ArticleClik here to view.
Akebia Announces Positive Top-Line Results from its Phase 2b Study of...
CAMBRIDGE, Mass. Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia...
View ArticleClik here to view.
NovaBay Pharmaceuticals Receives 2nd Major NeutroPhase Order for 150,000...
EMERYVILLE, Calif. NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, today...
View ArticleClik here to view.
ZRG Partners Life Sciences Hiring Index Shows Double Digit Increases Over 2013
WEST ORANGE, N.J. ZRG Partners, Inc. announces the results of its third quarter Global Life Sciences Hiring Index. The Index posts its highest score in nearly five years, even with the European...
View ArticleClik here to view.
Cardiovascular Systems Enrolls First Seven Patients in Japan for Coast Study
ST. PAUL, Minn. Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), announced that the first seven patients in Japan have been enrolled in its Coronary Orbital Atherectomy System Trial (COAST) study....
View ArticleClik here to view.
三井化学推出新型镜片材料”UV+420cut(TM)”
东京 (美国商业资讯)–三井化学株式会社(Mitsui Chemicals, Inc.) (TOKYO:4183)（总裁兼首席执行官：Tsutomu Tannowa）宣布，该公司已开始销售一种新型突破性镜片材料。该材料有助于保护眼睛免受紫外(10-400nm)光线辐射，同时可阻挡400nm-420nm的波长光。...
View ArticleClik here to view.
Vantage Health Forms Strategic Partnership with Theranostics Laboratory
REDWOOD CITY, Calif. Vantage Health Inc., (OTCQB:VNTH) (“Vantage Health”) or (the “Company”) today announced that it has entered into a strategic partnership with Theranostics Laboratory, a...
View ArticleClik here to view.
エリテック、フランス金融市場庁からの許可第14-566号を受けて目論見書を公表
仏リヨン （ビジネスワイヤ） — 急性白血病および医療ニーズが満たされていないその他の腫瘍適応症を対象に革新的な「腫瘍飢餓化」治療薬を開発するフランスのバイオ製薬企業のエリテック（Paris:ERYP）（Euronext Paris: FR0011471135 – ERYP）は本日、目論見書の許可を取得したと発表しました。 許可の取得...
View ArticleClik here to view.
Hoya Announces Second Quarter Financial Results
TOKYO Hoya Corporation (TOKYO: 7741) today announced financial results for the second quarter ended September 30, 2014. During the quarter, revenues totaled 121,242 million yen, increasing by 18.6%...
View ArticleClik here to view.
エリテック、腫瘍分野での適応症拡大と臨床開発加速に向けた3000万ユーロの資金調達に成功
仏リヨン （ビジネスワイヤ） — 急性白血病および医療ニーズが満たされていないその他の腫瘍適応症を対象に革新的な「腫瘍飢餓化」治療薬の開発に当たっているフランスのバイオ製薬企業エリテック（Paris:ERYP）（Euronext Paris: FR0011471135 – ERYP）は本日、総額3000万ユーロの増資を成功裏に完了したと発表しました。 エリテックのGil...
View ArticleClik here to view.
Transgenomic and University of Melbourne Collaborate to Further Validate...
OMAHA, Neb. Transgenomic, Inc. (NASDAQ:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and...
View ArticleClik here to view.
Akebiaが慢性腎臓病に関連した貧血を伴う非透析患者を対象にAKB-6548を検討した第2b相試験で、優れて良好な結果が得られたと発表
米マサチューセッツ州ケンブリッジ （ビジネスワイヤ） — 低酸素誘導因子（HIF）の生物学を通じて腎臓病患者に革新的治療薬を提供することに傾注するバイオ製薬企業のAkebia Therapeutics,...
View ArticleClik here to view.
ImpediMed Announced Medicare Payment for New L-Dex® Category I Code
BRISBANE, Australia & SAN DIEGO ImpediMed (ASX:IPD) is pleased to announce today the Centers for Medicare and Medicaid Services (CMS) has published the valuation for CPT® Category I Code 93702...
View ArticleClik here to view.
New Technique by Phyathai 2 International Thailand Can Save Lives after...
BANGKOK It is said that whenever the heart stops beating for longer than 4 minutes, the brain would be dead. Neurological Center at Phyathai 2 International introduced the new technique in Thailand...
View Article